Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma

JAMA Dermatology

Volumn 150, Issue 3, 2014, Pages 307-311

  Park, June J ^a   Hawryluk, Elena B ^b   Tahan, Steven R ^b   Flaherty, Keith ^b   Kim, Caroline C ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CLOBETASOL; DABRAFENIB; INTERFERON; IPILIMUMAB; SORAFENIB; TRAMETINIB; VEMURAFENIB;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CONSERVATIVE TREATMENT; CUTANEOUS GRANULOMATOUS ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; GRANULOMATOUS INFLAMMATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MEDICAL HISTORY; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUNCH BIOPSY; STEROID THERAPY; TREATMENT DURATION; TUMOR VOLUME; VERY ELDERLY;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CLOBETASOL; DISEASE PROGRESSION; DRUG ERUPTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; LOWER EXTREMITY; MALE; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; RISK ASSESSMENT; SAMPLING STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84896067711     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.7919     Document Type: Article

References (15)

1. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147. (Pubitemid 41653105)
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. (Pubitemid 34716871)
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
4. Alcalá AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res. 2012;18(1):33-39.
5. Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol. 2013;27(1):11-18.
6. Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18(3):314-322.
7. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207-215.
8. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18): 1694-1703.
9. Brincker H. Sarcoid reactions in malignant tumours. Cancer Treat Rev. 1986;13(3):147-156. (Pubitemid 17218836)
10. Sacks EL, Donaldson SS, Gordon J, Dorfman RF. Epithelioid granulomas associated with Hodgkin's disease: clinical correlations in 55 previously untreated patients. Cancer. 1978;41(2):562-567. (Pubitemid 8289271)
11. O'Connell MJ, Schimpff SC, Kirschner RH, Abt AB, Wiernik PH. Epithelioid granulomas in Hodgkin disease: a favorable prognostic sign? JAMA. 1975;233(8):886-889.
12. Baselmans AH, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W. The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother. 2002;51(9): 492-498.
13. Robert C, Schoenlaub P, Avril MF, et al. Malignant melanoma and granulomatosis. Br J Dermatol. 1997;137(5):787-792. (Pubitemid 27496200)
14. Tsunoda K, Onodera H, Akasaka T. Case of malignant melanoma associated with a sarcoid reaction. J Dermatol. 2011;38(9):939-942.
15. Suárez-García C, Pérez-Gil A, Pereira-Gallardo S, Codes-Villena M, García-Escudero A, Miguel Camacho F. Interferon-induced cutaneous sarcoidosis in melanoma. Melanoma Res. 2009;19(6):391-394.